Document:

<PAGE>

                                                               September 4, 2000

Jack Rubin
6602 Forestshire Drive
Dallas, Texas 75230

Dear Mr. Rubin:

       Hotel Reservations Network, Inc., a Delaware corporation (the "COMPANY")
and you hereby agree as follows:

       1.    Effective September 5, 2000 (the "INITIAL TERMINATION DATE"), you
and the Company agreed that your employment as Chief Financial and Strategic
Officer of the Company shall terminate. Accordingly, effective as of such date,
you hereby resign from all positions you then occupy as an officer or director
of the Company and any subsidiary or affiliate of the Company. During the period
from September 6, 2000 through September 15, 2000, or such earlier date as the
Company elects (the "SUBSEQUENT TERMINATION DATE"), the Company agrees to employ
you, and you agree to be employed by the Company, subject to the terms,
conditions and provisions of this Agreement.

      (a)     Through the Subsequent Termination Date, your current salary of
$180,000 per annum will be paid to you, in accordance with the Company's payroll
practice as in effect from time to time.

      (b)     Through the Subsequent Termination Date, you will be entitled to
continue to participate in any welfare, health and life insurance and pension
benefit and incentive programs as may be adopted from time to time by the
Company on the same basis as that provided senior executives of the Company.

      (c)     During the period from the Initial Termination Date through the
Subsequent Termination Date, you agree to assist the Company in its reasonable
requests in connection with the transfer of your prior responsibilities as Chief
Financial and Strategic Officer to other persons.

      (d)    In partial consideration of your assistance with the transition of
your prior responsibilities as Chief Financial and Strategic Officer to other
persons, your agreement to provide assistance as described in Section 2(b), and
your execution of the Release of Claims provided in Section 8 hereof, the
Company shall pay to you a bonus, payable upon December 31, 2000, in the amount
of $50,000.

      (e)    During the period from the Initial Termination Date through the
Subsequent Termination Date, the Company shall reimburse you for all

<PAGE>

reasonable and necessary expenses incurred by you in performing your duties for
the Company, including, without limitation, your duties under paragraph 1(c)
above, on the same basis as senior executives of the Company and in accordance
with the Company's policies as in effect from time to time.

      (f)    Upon request, the Company will provide any potential new employers
with positive references and positive letters of recommendation regarding your
employment with the Company. In addition, the Company will provide you with a
letter of recommendation on Company letterhead from the Company CEO on or before
the Subsequent Termination Date.

   2. (a)     Following the Subsequent Termination Date, and PROVIDED that
you execute and deliver to the Company the Release of Claims in substantially
the form attached to your Employment Agreement dated December 12, 1999, the
Company will pay you during the Assistance Period (as defined below) at your
current salary rate of $180,000 per year in accordance with the Company's
payroll practice as in effect from time to time until the earlier of (x) March
15, 2001 or (y) your employment by a third party (such period being the
"ASSISTANCE PERIOD"). Your rights under COBRA to continue your medical benefits
and welfare benefits under the Company's group plans after the Subsequent
Termination Date will be set forth in a separate letter. Continuation of your
medical benefits pursuant to COBRA during the Assistance Period shall be at the
expense of the Company and shall thereafter be at your own expense.

      (b)     You agree that during the Assistance Period you will be available
by telephone to assist the Company in its reasonable requests in regard to the
transfer of your prior responsibilities. The Company agrees that such requests
will not interfere with any employment held by you after the Subsequent
Termination Date.

      (c)     The Company shall provide you with four tourist class round trip
tickets on Delta Airlines or one of its partners from D/FW International
Airport, Dallas Love Field, Chicago O'Hare or Chicago Midway to anywhere within
the continental United States. The tickets shall be issued on or before the
Subsequent Termination Date.

       3. The Company acknowledges and agrees that your right to purchase 25,000
shares of the Company's Class A common stock, par value $0.01 (the "COMMON
STOCK"), pursuant to options granted to you under the Employment Agreement dated
December 12, 2000, between you and the Company shall be, and hereby is,
immediately and fully vested on the Initial Termination Date, in accordance with
the terms of such Employment Agreement, and subject to the limitations therein.
Except as otherwise stated herein, such options shall continue to be governed in
all respects by the terms and conditions of the Company's 2000 Stock Plan and
the Stock Option Award Agreement entered into by the Company and you (including,
without limitation, the exercise price).

       4. The provisions of this Agreement are not intended to, nor shall they
be construed to, require that you mitigate the amount of any payment by the

                                       2
<PAGE>

Company to you provided for in this Agreement by seeking, accepting or
performing other employment.

      5.    The Company shall have the right to deduct from all payments under
this Agreement, whether in cash, stock or other property, amounts required to be
withheld by the Company under applicable tax laws.

      6.  (a)  You shall continue to be bound by the Noncompetition,
Nonsolicitation and Confidentiality Agreement executed in connection with your
Employment Agreement

      7.  (a)  You further agree and covenant that:

               (i) unless required by law, you shall not disclose the terms and
conditions of this Agreement to anyone other than your immediate family, tax
advisor, legal counsel or a governmental taxing authority; provided that if you
are asked about the terms of your separation from the Company you may say that
you and the Company have agreed to a fair severance arrangement;

               (ii) you shall not make any untruthful and disparaging statements
about the Company or any of its affiliates to any clients, competitors,
suppliers, employees or former employees of the Company or any of its affiliates
or other persons (including but not limited to the press or other media).

          (b)  The Company shall not (i) disseminate the terms and conditions of
this Agreement to employees of the Company generally or (ii) make any untruthful
and disparaging statements about you to any of the Company's clients,
competitors, suppliers, employees or prospective employees, your prospective
employers or other persons (including but not limited to the press or other
media). The Company shall have the right to issue press releases in connection
with this Agreement. Any description of your separation from the Company in such
press release shall be consistent with the description in Section 1 hereof. The
Company agrees to provide you with a copy of any such press release, to consider
your comments prior to its issuance, and to make any reasonable changes to such
press release as you may request.

          8.   Prior to the Subsequent Termination Date, you shall execute the
Release of Claims substantially in the form attached as Exhibit A to your
Employment Agreement. For and in consideration of the promises made by you
herein and other good and valuable consideration, the Company hereby releases,
waives and forever discharges you and your heirs, successors and assigns from
any and all actions or claims under any local, state or federal law, for any
type of claim, demand or action whatsoever, arising out of or in connection with
your employment with the Company, other than claims to enforce the terms of this
agreement.

          9.   This Agreement and all matters or issues related hereto shall be
governed by the laws of the State of Texas applicable to contracts entered into
and performed therein. Whenever possible, each provision of this Agreement shall
be interpreted in such a manner as to be effective and valid under applicable
law, but if any

                                       3
<PAGE>

provision of this Agreement shall be prohibited by or invalid under such law,
such provision shall be ineffective to the extent of such prohibition or
invalidity, without invalidating the remainder of such provision or the
remaining provisions of this Agreement. The Company hereby consents to, and you
hereby submit your person to, the jurisdiction of the state courts of the State
of Texas sitting in Dallas County, and the United States District Court for the
Northern District of Texas, for the purposes of the enforcement of this
Agreement. All disputes under this Agreement will be determined in the Federal
or State courts within the State of Texas sitting in Dallas County.

          10. (a) This Agreement is personal in its nature and the parties shall
not, without the prior written consent of the other, assign or transfer this
Agreement or any rights or obligations hereunder; PROVIDED, HOWEVER, the
provisions hereof shall inure to the benefit of, and be binding upon, (i) each
successor of the Company or any of its affiliates, whether by merger,
consolidation or transfer of all or substantially all of its assets and (ii)
your heirs, legatees, executors, administrators and legal representatives.

              (b) This Agreement and, as to the Option, the Company's 2000
Stock Option Plan and the Stock Option Award Agreement referenced herein,
contain the entire understanding of the parties hereto relating to the subject
matter herein contained and supersede all prior agreements or understandings
between the parties hereto with respect thereto, including, without limitation,
the Employment Agreement, dated December 12, 1999, between you and the Company,
and can be changed only by a writing signed by both parties hereto. No waiver
shall be effective against either party unless in writing and signed by the
party against whom such waiver shall be enforced.

          11. All notices and other communications hereunder shall be deemed to
be sufficient if in writing and delivered in person or by a nationally
recognized courier service or duly sent by facsimile, addressed, if to you, to
the address set forth above; and if to the Company, to Hotel Reservations
Network, Inc., 8140 Walnut Hill Lane, Suite 800, Dallas, Texas 75231, Attn:
Chief Executive Officer, Facsimile No. 214.265.0974, or such other address as
you or the Company, as the case may be, may have last furnished to the other by
notice in writing. Each notice delivered in person or by overnight courier shall
be deemed given when delivered or when delivery is attempted and refused. Each
notice delivered by facsimile transmission, shall be deemed delivered on the
date on which the sender receives confirmation that such was received by the
addressee if during business hours or on the next business day if not.

          12. This Agreement may be executed in two or more counterparts, all of
which shall be considered one and the same agreement.

          BY SIGNING THIS AGREEMENT, YOU STATE THAT:

               (a) YOU HAVE READ THIS AGREEMENT AND HAVE HAD SUFFICIENT TIME TO
CONSIDER ITS TERMS;

                                       4
<PAGE>

               (b) YOU UNDERSTAND ALL OF THE TERMS AND CONDITIONS OF THIS
AGREEMENT AND KNOW THAT YOU ARE GIVING UP IMPORTANT RIGHTS;

               (c) YOU AGREE WITH EVERYTHING IN THIS AGREEMENT;

               (d) YOU ARE AWARE OF YOUR RIGHT TO CONSULT WITH AN ATTORNEY
BEFORE SIGNING THIS AGREEMENT AND HAVE BEEN ADVISED OF SUCH RIGHT;

               (e) YOU HAVE SIGNED THIS AGREEMENT KNOWINGLY AND VOLUNTARILY; AND

               (f) THIS AGREEMENT INCLUDES A RELEASE BY YOU OF ALL KNOWN AND
UNKNOWN CLAIMS.

         If the foregoing correctly sets forth our understanding, please sign
one copy of this Agreement and return it to the undersigned, whereupon this
letter shall constitute a binding agreement between us.

                                     Sincerely,

                                     HOTEL RESERVATIONS NETWORK, INC.

                                     By:           /s/ David Litman
                                            ----------------------------------
                                            Name:  David Litmant
                                            Title:  Chief Executive Officer

ACCEPTED AND AGREED:

            /s/ Jack Rubin
--------------------------------------------
               Jack Rubin

                                       5Prepared by MERRILL CORPORATION www.edgaradvantage.com

QuickLinks
 -- Click here to rapidly navigate through this document
 

REDACTED VERSION  

  
      CLINICAL MANUFACTURE AND SUPPLY AGREEMENT         

    THIS AGREEMENT (the "Agreement") is entered into on September 1, 2000 by and between ABC Laboratories, Inc., of Columbia, Missouri ("ABC") and
NeoRx Corporation, of Seattle, Washington ("NeoRx"). 

WITNESSETH  

    WHEREAS, ABC desires to manufacture 166Ho-DOTMP at the radiopharmaceutical manufacturing facility located in Columbia, Missouri (the
"Facility"); and 

    WHEREAS,
NeoRx desires that ABC manufacture and supply to and on behalf of NeoRx, and ABC is willing to manufacture and supply, certain quantities of holmium-166
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-methylenephosphonic acid (166Ho-DOTMP) (the "Product") for NeoRx's use in clinical trials,
all in accordance with the terms and conditions set forth in this Agreement; 

    NOW
THEREFORE, in consideration of the foregoing promises and agreements set forth herein, the parties agree as follows: 

AGREEMENT  

I.  Scope of Work  

    (A)  Processing Responsibilities.  ABC will (1) manufacture, analyze, package in dosage form, and
inspect and label (collectively "Process") Product at the Facility in accordance with cGMP and the Product specifications set forth on Exhibit A (which is incorporated herein by reference,
unless NeoRx Quality Assurance approves (on a per batch basis) any deviation in batch test result(s) from Product specifications and releases the Product batch for administration to a patient. In
order to meet this responsibility ABC must [*]. (2) maintain records regarding the Product in conformity with cGMP, and (3) supply the Product to NeoRx in such
doses as NeoRx may order from ABC in accordance with this Agreement as allowable by MURR HP. 

    (B)  Additional Responsibilities.  In addition to the responsibilities stated in clause (A) above,
ABC agrees that it will have the responsibilities listed on Exhibit B (which is incorporated herein by this reference) with respect to Processing the Product. 

[*] designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the
Commission.

II.  Purchase Orders  

    (A)  Purchase Orders.  NeoRx will deliver to ABC by the close of business on Monday of each week during
the term of this Agreement, a written or electronic purchase order for the number of full or partial batches, and whether each batch is a [*], that NeoRx desires to purchase
for delivery during the following calendar week. Each purchase order will also specify the delivery dates and the number doses of Product that are to be shipped to each location. Each dose shall be
shipped in such manner, and to such location, as directed by NeoRx and permitted by MURR HP. 

    (B)  Contradictory Provisions.  To the extent any purchase order, or related invoice, contains any
provisions contrary to the terms of this Agreement, such contrary provisions shall have no force or effect and the terms of this Agreement shall control. 

21

III.  Fees  

    (A)  Milestone Payments.  NeoRx agrees that it will pay to ABC the milestone payment as described in
Exhibit C (which is incorporated herein by this reference). 

    (B)  Reimbursable Expenses.  NeoRx shall reimburse ABC for the expenses listed on Exhibit D. The
parties acknowledge that NeoRx may request an increase to its production capacity at the Facility in order to timely Process the amount of Product contemplated by the Parties in this Agreement. To
facilitate the timely scaling of ABC's production capacity, NeoRx agrees that it will reimburse ABC for labor expenses at a rate of [*] and [*] incurred
by ABC; provided, however, that ABC will pay for changes in cask design and cask construction required to scale up the Process with the acknowledgement by both parties that ABC will obtain ownership
of those specific cask and cask construction modifications at the conclusion of this agreement. ABC agrees that it must obtain NeoRx's prior written consent prior to incurring any expense not listed
on Exhibit D for which it intends to seek reimbursement from NeoRx. 

    (C)  Batch Fee.  For each batch of Product processed by ABC during the term of this Agreement, NeoRx
shall pay to ABC a fee of (1) [*], (2) [*], and (3) [*]. The price per batch includes the cost of labor,
material and overhead to manufacture and test the finished vials of Product, but is exclusive of the cost of 166 holmium chloride, DOTMP, MURR radiation safety oversight and production supervision,
and shipping expenses all of which shall be paid by NeoRx separately. 

    (D)  Minimum Purchases.  During the period from the effective date of this agreement until
December 22, 2000, NeoRx agrees to purchase a minimum of [*]. 

    (E)  MURR Radiation Safety Oversight and Production Supervision Fees.  NeoRx shall pay to ABC a fee of
[*] that ABC manufactures product at NeoRx's request. 

    (F)  Facility Lease Fees.  During the term of this contract NeoRx shall pay to ABC a fee of
[*], [*], and [*] to Process Product. 

IV.  Billing And Payment Terms  

    ABC shall invoice NeoRx bi-weekly for any Product Processed and supplied to or on behalf of NeoRx in response to purchase orders during the two
weeks prior to the date of each invoice. NeoRx shall pay for such Product within thirty (30) days of its receipt of such invoice. All invoices that remain unpaid after sixty (60) days of
NeoRx's receipt thereof shall accrue interest at the rate of 1.5% per month. ABC shall reference the applicable purchase orders on all invoices. If NeoRx disagrees for any reason with an amount of an
invoice, NeoRx shall notify ABC in writing of such a disagreement within ten (10) business days of receipt of such invoice, and the parties shall promptly endeavor to resolve the dispute in
good faith. 

V.  Shipping Terms  

    NeoRx will be responsible for the shipment of the Product. NeoRx, in consultation with ABC, shall arrange for the shipment of the Product from the Facility to
NeoRx, or such other location as determined by NeoRx. NeoRx shall be responsible for the payment of all shipping charges (including, without limitation, freight, handling, insurance and all other
transportation-related items associated with such shipments). NeoRx shall make all payments directly. 

VI.  Term And Termination  

    This Agreement will continue through December 31, 2002; provided, however, that either party may terminate this agreement after December 22, 2000
upon 30 days prior written notice; and provided, however, that either party may terminate this Agreement if the other party breaches any of 

22

its obligations hereunder and does not cure such breach within ten (10) days of written notice. Upon termination or expiration of this agreement or should NeoRx's cumulative batch fees (net of
MURR charges) to ABC fall below [*] will be transferred from NeoRx to ABC; provided, however, that ABC will keep the Facility intact and permit NeoRx and FDA inspectors to
access and inspect the Facility
and Process to ensure that the Product is manufactured and released in accordance with cGMP and the Product specifications as set forth on Exhibit A through the year 2002. 

VII.  Miscellaneous  

    (A) Each
party may receive information from the other party that the receiving party should reasonably believe is confidential. Each party will hold the other party's
confidential information in confidence, including the terms of this Agreement, and will disclose such information to persons on a need to know basis only. 

    (B) This
Agreement contains the entire understanding of the parties and supersedes all prior agreements and understandings, and may not be modified, nor any term
waived, except by the unanimous written consent of the parties. 

    (C) The
parties are acting as independent contractors and independent employers. Nothing herein shall be construed as creating a partnership, joint employer or agency
relationship between the parties and no party shall have authority to bind the other in any respect. 

    (D) In
the event any provision of this Agreement is held unenforceable under applicable law, the remainder of the Agreement shall remain valid. 

    (E) No
patent, trademark, logo, copyright or other intellectual property rights are conveyed by this Agreement, and neither party shall have the right to use the other
parties intellectual property for any purpose whatsoever without prior written consent. 

    (F) The
parties acknowledge that the execution of this agreement relieves any perceived outstanding obligations associated with ABC quote #Jparkins.4E, "Design,
Construction, and Validation of Processing Box for Phase III Clinical Manufacture of 166HoDOTMP". 

    (G) NeoRx
agrees to take responsibility for payment of completion, shipping, and installation charges [*]. ABC will be held harmless for these
payments. 

    (H) During
the Term of this Agreement, neither Party shall make any press release or other disclosure of the terms of this Agreement without the prior written consent
of the other Party. 

    (I) Each
Party shall defend, indemnify, and hold harmless the other Party, its officers, agents, employees and Affiliates (collectively, the "Indemnified Party") from
any third party loss, claim, action, damage, expense or liability (including defense costs and reasonable attorneys' fees) arising out of the Indemnifying Party's (a) breach, violation or non
fulfillment of any of its covenant, agreements, representations or warranties under this Agreement, (b) handling, possession, or use of the Product, (c) negligence or willful misconduct,
or (d) breach of any third party's trade secret right, except to the extent that such loss, claim, action, damage, expense or liability is based on, arises out of, or is due to the negligence
or willful misconduct of, or breach of this Agreement by the Indemnified Party. 

23

    IN WITNESS WHEREOF, each party has caused this Agreement to be executed by a duly authorized representative, effective on this date first set forth above. 

	 
	 	 
	 	 
	 	 

	NEORX CORPORATION	 	ABC LABORATORIES, INC.
	 

By:	 
 	 

	 
 	 

By:	 
 	 

	 

Name:	 
 	 

	 
 	 

Name:	 
 	 

	 

Title:	 
 	 

	 
 	 

Title:	 
 	 

	 

 	 
 	 

 	 
 	 

 	 
 	 

 

24

  EXHIBIT A
       Item Specifications         

    [*] 

25

 EXHIBIT A (continued)

    [*]

26

  EXHIBIT B
       ABC's ADDITIONAL RESPONSIBILITIES         

    (1) Be
capable of Processing up to [*] of Product per week for delivery on Tuesday through Thursday of each such week as permitted by MURR HP 

    (2) Perform
scale up of Process from [*] and be capable of Processing up to [*] Product per week for delivery on Tuesday
through Thursday of each such week at NeoRx's request; provided, however, NeoRx provides a reasonable amount of time for ABC to complete the Process scale up as permitted by MURR HP. 

    (3) Perform
all QA/QC release testing on each batch of Product as required pursuant to cGMP and the Product specifications set forth on Exhibit A. 

    (4) Maintain
the manufacturing process and Facility in accordance with cGMP. ABC agrees that to evidence its compliance with this responsibility, ABC will conduct all
of the following by September 4, 2000: 

    (a) Completion
of technology transfer tasks as defined in protocol to be provided to ABC by NeoRx; 

    (b) IQ/OQ/PQ
of all Process and analytical equipment and instrumentation except for [*] which will be completed as soon as reasonably possible; 

    (c) Process
[*] that meets cGMP and all Product specifications set forth on Exhibit A. This responsibility can also be met if NeoRx
Quality Assurance approves any deviation in batch test result(s) from Product specifications and releases the Product batch for administration to a patient. 

    (5) Procure,
test, release, and maintain sufficient inventory of raw materials, manufacturing and QC components and reagents necessary to Process the Product in
accordance with this Agreement, other than DOTMP and 166HoC13 which will be supplied by NeoRx and MURR, respectively. 

    (6) Make
available to NeoRx and any applicable governmental agency all records relating to the manufacturing process and Facility as they relate to the Product. 

    (7) Permit
NeoRx and FDA inspectors to access and inspect the Facility to ensure that the Product is being Processing in accordance with cGMP and the Product
specifications as set forth on Exhibit A as permitted by MURR HP. 

    (8) Provide
to NeoRx a certificate of analysis in the form as agreed to by the parties and in compliance with all laws, for each batch of Product, provided a
certificate of analysis is proved to ABC Labs by MURR before production is complete. 

    (9) Dispose
of all waste resulting from the manufacture of the Product. 

27

  EXHIBIT C
       MILESTONE PAYMENTS         

    NeoRx will pay to ABC each of the following milestone payments upon ABC successfully completing (to NeoRx's reasonable satisfaction) the application milestone: 

    Payment:  [*]. Milestone: Validation,
qualification, and technology transfer services upon demonstration of a [*] qualification batch meeting Product specifications set forth on Exhibit A. This
responsibility can also be met if NeoRx Quality Assurance approves any deviation in batch test results(s) from Product specifications and releases the Product batch for administration to a patient. 

    Payment  [*] Milestone: Payment for HPLC
software upon receipt of manufacturers invoice. 

    Payment  [*] Milestone: Payment for MURR HP upon
execution of this agreement. 

    Payment:  [*]. Milestone: Execution of this
agreement. 

    Payment:  [*]. Milestone: Complete resolution of
any cGMP compliance deficiencies noted during the 8/22/00 NeoRx quality audit of ABC, and upon demonstration of 12 weeks of batch production suitable for patient dosing. 

28

  EXHIBIT D
       REIMBURSABLE EXPENSES         

    (A) Packaging and Handling Fees. NeoRx shall reimburse ABC at a rate of [*] of Product. ABC
shall provide a monthly invoice to NeoRx of these fees. 

    (B) Radiation Waste (Low Specific Activity) Fees. NeoRx shall reimburse ABC at a rate of [*] of
low specific activity (Ho-166m) waste. ABC shall notify NeoRx in writing when each barrel is due for disposal. 

    (C) HPGe Detector Technical Support Fees. NeoRx shall reimburse ABC at a rate of [*] of MURR
technical support required to service the HPGe Detector. ABC shall notify NeoRx in writing when MURR service is required. 

    (D) Maintenance and Repair of Equipment and Instrumentation. NeoRx shall reimburse ABC for maintenance and repair of the
equipment and instrumentation listed on Exhibit E for the period that NeoRx maintains ownership of the listed equipment and instrumentation. 

29

  EXHIBIT E
       EQUIPMENT AND INSTRUMENTATION         

[*] 

30

QuickLinks

CLINICAL MANUFACTURE AND SUPPLY AGREEMENT

EXHIBIT A Item Specifications

EXHIBIT B ABC's ADDITIONAL RESPONSIBILITIES

EXHIBIT C MILESTONE PAYMENTS

EXHIBIT D REIMBURSABLE EXPENSES

EXHIBIT E EQUIPMENT AND INSTRUMENTATION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00017-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00017-of-00352.parquet"}]]